Estrogen therapy for castrate resistant prostate cancer

雌激素治疗去势抵抗性前列腺癌

• 批准号: nhmrc : 1020959
• 负责人: Prof Gail Risbridger
• 金额: $ 35.45万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2014-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/estrogen-therapy-castrate-prostate-cancer/110078
• 关键词: Estrogen; therapy; castrate; resistant; prostate

Withdrawal of male hormones in men with prostate cancer is effective therapeutically because it causes cell death in most of the tumour. However the remaining cells (called castrate resistant cells), give rise to recurrent disease that inevitably kills the patient. This project aims to test if our compound will kill these cells and prevent recurrence or if it has any benefit for the patients who have incurable disease.

对前列腺癌患者停用雄性激素在治疗上是有效的，因为它会导致大部分肿瘤细胞死亡。然而，剩余的细胞（称为去势抵抗细胞），引起复发性疾病，不可避免地杀死患者。该项目旨在测试我们的化合物是否会杀死这些细胞并防止复发，或者它是否对患有不治之症的患者有任何好处。